tirofiban has been researched along with Angina at Rest in 123 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (26.02) | 18.2507 |
| 2000's | 85 (69.11) | 29.6817 |
| 2010's | 5 (4.07) | 24.3611 |
| 2020's | 1 (0.81) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, L; Jia, HZ; Li, MC; Zhu, W | 1 |
| Chen, Y; Gao, CY; Li, MW; Rao, LX; Zhao, XM; Zhu, ZY | 1 |
| Barbieri, L; De Luca, G; Marino, P; Schaffer, A; Verdoia, M | 1 |
| Avakian, SD; Caribé, PM; Mansur, Ade P; Roggerio, A; Strunz, CM; Takada, JY | 1 |
| Beiras-Fernandez, A; Jiru, P; Kowert, A; Reichart, B; Schmoeckel, M; Spannagl, M; Weis, M | 1 |
| Brener, SJ | 1 |
| Collins, MB; Dangas, G; Hooper, WC; Kreps, EM; Lansky, AJ; Leon, MB; Mehran, R; Moses, JW; Saltzman, AJ; Stone, GW; Weisz, G | 1 |
| Califf, RM; Kandzari, DE | 1 |
| Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP | 1 |
| Alpert, JS; Antman, EM; Beasley, JW; Braunwald, E; Califf, RM; Cheitlin, MD; Faxon, DP; Fuster, V; Gibbons, RJ; Gregoratos, G; Hiratzka, LF; Hochman, JS; Jacobs, AK; Jones, RH; Kereiakes, D; Kupersmith, J; Levin, TN; Pepine, CJ; Schaeffer, JW; Smith, EE; Smith, SC; Steward, DE; Theroux, P | 1 |
| Alexander, C; Becker, ER; Cannon, CP; Chu, H; Cook, JR; Culler, S; Demopoulos, LA; DiBattiste, PM; Jurkovitz, CT; Kosinski, AS; Mahoney, EM; Nag, S; Robertson, DH; Weintraub, WS | 1 |
| Braunwald, E; Cannon, CP; DiBattiste, PM; Januzzi, JL; Murphy, S; Weintraub, W | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Glaser, R; Herrmann, HC; Murphy, SA | 1 |
| Boussaada, R; Chérif, A; Ezzar, T; Mechmèche, R; Messaoudi, H; Mourali, S | 1 |
| Antman, EM; Sabatine, MS | 1 |
| Hobbach, HP; Schuster, P | 1 |
| Boura, J; Dixon, SR; Grines, CL; Harjai, KJ; Karatepe, M; Moses, JW; Moussa, I; O'Neill, WW; Roubin, GS; Soffer, D | 1 |
| Böhm, M; Fries, R | 1 |
| Dambrink, JH; de Boer, MJ; de Vries, ST; Gosselink, AT; Hoorntje, JC; Miedema, K; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Auer, J; Berent, R; Eber, B; Lassnig, E; Maurer, E; Weber, T | 1 |
| Cakmak, M; Cam, N; Okmen, E; Tartan, Z | 1 |
| Alemao, E; Bakhai, A; Ben-Joseph, R; Collinson, JR; Flather, MD; Itzler, R; Normand, C; Stevens, W | 1 |
| Antman, EM; Bates, ER; Cohen, M; Every, NR; Ferguson, JJ; Harrington, RA; Pepine, CJ; Theroux, P | 1 |
| Huynh, T; Snapinn, S; Theroux, P; Wan, Y | 1 |
| Merlini, PA; Rossi, ML | 1 |
| Cam, N; Okmen, E; Ozen, E; Sanli, A; Tartan, Z; Uyarel, H | 1 |
| Adgey, AA; Manoharan, G | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS; Weintraub, WS | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Rifai, N; Sabatine, MS; Wiviott, SD | 1 |
| Gill, DS; Ng, K; Ng, KS | 1 |
| Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP | 1 |
| De Caterina, R; Zimarino, M | 1 |
| Aydin, M; Bilge, M; Ozeren, A; Ozkökeli, M; Unalacak, M | 1 |
| Hennebry, TA; Saucedo, JF | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Murphy, SA; Singh, KP | 1 |
| Gandhi, PJ; Silva, MA | 1 |
| Cannon, CP; Dibattiste, PM; Gibson, CM; Karha, J; Murphy, SA | 1 |
| DiBattiste, PM; Huynh, T; Pharand, C; Piazza, N; Snapinn, SM; Theroux, P; Wan, Y | 1 |
| Ardissino, D; Menozzi, A; Merlini, PA | 1 |
| Aroney, CN; Gunasekara, AP; Walters, DL | 1 |
| Baum, H; Braun, S; Dibra, A; Dirschinger, J; Hadamitzky, M; Kastrati, A; Mehilli, J; Schömig, A; Schühlen, H | 1 |
| Chang, M; Dangas, G; Ellis, SG; Kao, J; Laufer, N; Mehran, R; Russell, ME; Stone, GW; Tannenbaum, MA; Teirstein, PS; Watkins, M | 1 |
| Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A | 1 |
| Baglini, R; Capuano, C; Danzi, GB; Mauri, L; Predolini, S; Sesana, M | 1 |
| Glaser, R; Glick, HA; Herrmann, HC; Kimmel, SE | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Bonizzoni, E; De Servi, S; Dellavalle, A; Leoncinie, M; Mariani, M; Poletti, F; Politi, A; Vandoni, P | 1 |
| Alexander, KP; Chen, AY; Gibler, WB; Hochman, JS; Newby, LK; Ohman, EM; Peterson, ED; Redberg, RF; Roe, MT; Schwartz, JB | 1 |
| Alessi, MC; Barbou, F; Bonnet, JL; Cuisset, T; Frère, C; Hovasse, T; Quilici, J; Said, LN | 1 |
| Cannon, CP; Chen, AY; Gibler, WB; Gibson, CM; Greenbaum, AB; Harrington, RA; Hoekstra, JW; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tricoci, P | 1 |
| Song, Y | 1 |
| Arora, R; Deo, D; Deshpande, NV; Hiremath, JS; Hiremath, MS; Joseph, J; Khan, A; Mardikar, HM; Mathew, R; Moliterno, DJ; Mukherjee, D | 1 |
| Delgado, C; Fernández-Perez, GC; Rodríguez-Pérez, J; Vázquez, M; Vázquez-Lima, A; Velasco, M | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Anderson, KM; Coller, BS; Weisman, HF | 1 |
| Gawaz, M; Neumann, FJ; Schömig, A | 1 |
| Karlberg, KE; Martinsson, A; Mattsson, E; Nyqvist, O; Rasmanis, G; Sylvén, C | 1 |
| Moliterno, DJ; Steinhubl, SR | 1 |
| Badimon, JJ; Chesebro, JH | 1 |
| Adgey, AA | 1 |
| Armstrong, PW; Braunwald, E; Califf, RM; Gibler, WB; Hamm, CW; Maseri, A; Simoons, ML; Van de Werf, F | 1 |
| Cohen, DJ; Deckelbaum, LI; Gibson, CM; Goel, M; Harris, KE; King, SB; Piana, RN | 1 |
| Béguin, S; de Zwaan, C; Hemker, HC; Keularts, IM | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; Gormley, GJ; Robertson, DH; Weintraub, WS | 1 |
| Liron, M | 1 |
| Kleiman, NS; Ramanathan, A | 1 |
| Dykun, Y; Ronner, E; Simoons, ML; van den Brand, MJ; van der Wieken, LR | 1 |
| Frojmovic, M; Théroux, P; Xiao, Z | 1 |
| Al-Mousa, EN; Arshad, MN; Campsey, M; Gandhi, R; Gibson, CM; Marble, SJ; Mattson, S; Mesley, R; Moynihan, JL; Murphy, S; Ryan, KA; Swanson, J | 1 |
| Phillips, J; Stouffer, GA; Subbarao, VD | 1 |
| Klein, WW | 1 |
| Kiowski, W; Meyer, BJ; Szucs, TD | 1 |
| Abbottsmith, CW; Broderick, TM; Hattemer, C; Kereiakes, DJ; Lacock, P; Mueller, M; Roth, EM; Runyon, JP; Schneider, J; Shimshak, T; Whang, D | 1 |
| Tcheng, JE | 1 |
| Sax, FL; Snapinn, SM; Théroux, P; Zhao, XQ | 1 |
| Akkerhuis, KM; Boersma, E; Califf, RM; Simoons, ML; Théroux, P; Topol, EJ | 1 |
| Abbottsmith, CA; Anderson, LC; Blanck, C; Broderick, TM; Howard, W; Kereiakes, DJ; Lacock, P; Mueller, M; Roth, EM; Schneider, J; Whang, D | 1 |
| Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD | 1 |
| Wallentin, L | 1 |
| Lincoff, AM; Roe, MT; Sapp, SK | 1 |
| Amidon, JB; Amidon, TM; Benson, JM; Coffler, D | 1 |
| Cohen, M | 2 |
| Collinson, J; Flather, M; Gomma, A; Purcell, H | 1 |
| Chadow, HL; Giarraffa, L; Gunsburg, MY; Hauptman, RE; Rafii, SE; Strom, JA; VanAuker, M | 1 |
| Holmes, DR | 1 |
| Bhatt, DL; Topol, EJ | 1 |
| Chae, CU; Giugliano, R; Hahn, SS; Jang, IK; Januzzi, JL; Lewandrowski, K; Theroux, P | 1 |
| Braunwald, E; Califf, RM; Cannon, CP; Fox, KA; Fuster, V; Gibler, WB; Harrington, RA; King, SB; Kleiman, NS; Theroux, P; Topol, EJ; Van de Werf, F; White, HD; Willerson, JT | 1 |
| Alexander, J; Barr, E; Ghannam, AF; Pharand, C; Sax, FL; Snapinn, S; Théroux, P | 1 |
| Rasmanis, G; Sylvén, C | 1 |
| Agustí, A; Araujo, R | 1 |
| Deckelbaum, LI; Dodge, JT; Dotani, I; Gibson, CM; Goel, M; King, SB; Marble, SJ; Murphy, SA | 1 |
| Mitka, M | 1 |
| Droullé, C; Garnotel, R; Hézard, N; Metz, D; Nguyen, P; Potron, G | 1 |
| Hamm, C | 1 |
| Bachmann, LM; Golder, S; Kleijnen, J; McDonagh, MS; ter Riet, G | 1 |
| Alexander, J; Barr, E; Dupuis, J; Gervais, P; Grandmont, D; Huynh, T; Kouz, S; Laramée, P; Pesant, Y; Sax, FL; Théroux, P | 1 |
| Berkowitz, SD | 1 |
| Husted, SE; Rasmussen, S | 1 |
| Cannon, CP; Cohen, MC; Hochman, JS; Lucore, CL; O'Rourke, RA; Popma, JJ | 1 |
| Bassand, JP | 1 |
| Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T | 1 |
| Goldmann, BU; Hamm, CW | 1 |
| Adam, PC; Evemy, KL; Pemberton, J | 1 |
| Vernon, SM | 1 |
| Braunwald, E; Cannon, CP; DeLucca, PT; Demopoulos, LA; DiBattiste, PM; Frey, MJ; Gibson, CM; Lakkis, N; Neumann, FJ; Robertson, DH; Vicari, R; Weintraub, WS | 1 |
| Jang, IK; Januzzi, JL; Sabatine, MS; Snapinn, S; Théroux, P | 1 |
| Lassila, R | 1 |
| Gazewood, J | 1 |
| Popma, JJ; Suk, J | 1 |
| Chew, DP; Moliterno, DJ | 1 |
| Antman, EM; Braunwald, E; McCabe, CH; Morrow, DA; Snapinn, SM; Theroux, P | 1 |
| Campbell, P | 1 |
| DiBattiste, PM; Herrmann, HC; Hirshfeld, JW; Kapoor, S; Klugherz, BD; Kolansky, DM; Magness, K; Swierkosz, TA; Tardiff, DC; Valettas, N; Wilensky, RL | 1 |
| Bhatt, DL; Chew, DP | 1 |
| Dauterman, KW; Dodge, JT; Dotani, MI; Gibson, CM; Marble, SJ; Michaels, AD; Murphy, SA | 1 |
39 review(s) available for tirofiban and Angina at Rest
| Article | Year |
|---|---|
TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2002 |
[Stratification of cardiac risk in unstable angina: value of troponin measurements].
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Electrocardiography; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Factors; Time Factors; Tirofiban; Troponin; Troponin I; Troponin T; Tyrosine | 2002 |
The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Drug Therapy, Combination; Heparin; Humans; Logistic Models; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Recurrence; Risk Assessment; Thrombolytic Therapy; Tirofiban; Troponin; Tyrosine | 2003 |
Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Eptifibatide; Fibrinolytic Agents; Forecasting; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Myocardial Infarction; Peptides; Placebos; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Time Factors; Tirofiban; Tyrosine | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Topics: Abciximab; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Controlled Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Emergencies; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Time Factors; Tirofiban; Tyrosine | 2003 |
[Role of GP IIb/IIIa blockers in clinical cardiology].
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myocardial Ischemia; Randomized Controlled Trials as Topic; Risk Assessment; Thrombolytic Therapy; Tirofiban; Tyrosine | 2002 |
Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Comorbidity; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2004 |
Use of the early invasive approach in the management of acute coronary syndromes.
Topics: Angina, Unstable; Cardiac Catheterization; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2004 |
Tirofiban in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 2005 |
The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Fusion Proteins; Thrombosis; Tirofiban; Tyrosine | 1996 |
[Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
Topics: Abciximab; Acetates; Alkynes; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Binding Sites; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Coronary Disease; Double-Blind Method; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Receptors, Cell Surface; Time Factors; Tirofiban; Tyrosine | 1997 |
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 1997 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Angioplasty; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Ischemia; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1998 |
Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Disease Progression; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Tyrosine | 1998 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Electrocardiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 1999 |
Efficacy of low-molecular-weight heparin in acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Biomarkers; Drug Therapy, Combination; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Secondary Prevention; Survival Rate; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2000 |
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
Treatment of unstable angina: the role of platelet inhibitors and anticoagulants.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary Thrombosis; Endothelium, Vascular; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein receptor site blockade in coronary artery disease.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Drug Therapy, Combination; Eptifibatide; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2000 |
Redefining medical treatment in the management of unstable angina.
Topics: Abciximab; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Diagnosis, Differential; Enoxaparin; Eptifibatide; Government Agencies; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; National Institutes of Health (U.S.); Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Risk; Time Factors; Tirofiban; Troponin I; Troponin T; Tyrosine; United States | 2000 |
[Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
Topics: Abciximab; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Platelets; CD18 Antigens; Chemotaxis, Leukocyte; Coronary Artery Bypass; Coronary Disease; Cytokines; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Leukocytes; Ligands; Macrophage-1 Antigen; Membrane Glycoproteins; Models, Biological; Myocardial Infarction; Neutrophils; P-Selectin; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombospondins; Tirofiban; Tyrosine | 2000 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.
Topics: Acetates; Angina, Unstable; Biphenyl Compounds; Cost-Benefit Analysis; Eptifibatide; Female; Humans; Male; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Pyrrolidines; Tirofiban; Tyrosine | 2000 |
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration | 2000 |
[Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Fibrinolytic Agents; Humans; Injections, Intravenous; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2001 |
New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Algorithms; Angina, Unstable; Antithrombins; Biomarkers; Diagnosis, Differential; Electrocardiography; Eptifibatide; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Tyrosine | 2001 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Complications; Drug Therapy, Combination; Eptifibatide; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Oligosaccharides; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Factors; Thrombocytopenia; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Nitrates; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Terminology as Topic; Ticlopidine; Tirofiban; Tyrosine | 2001 |
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Nadroparin; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Thrombosis; Tirofiban; Transaminases; Tyrosine | 2001 |
Use of coronary revascularization in patients with unstable and non-ST-segment elevation acute myocardial infarction.
Topics: Angina, Unstable; Humans; Myocardial Infarction; Myocardial Revascularization; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome; Thrombolytic Therapy; Tirofiban; Tyrosine | 2001 |
GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Atherectomy; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Syndrome; Time Factors; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2001 |
Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Syndrome; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
42 trial(s) available for tirofiban and Angina at Rest
| Article | Year |
|---|---|
[The clinical efficacy and safety of fondaparinux combined with tirofiban hydrochloride in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention].
Topics: Adult; Aged; Angina, Unstable; Anticoagulants; Female; Fondaparinux; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polysaccharides; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Time Factors; Tirofiban; Tyrosine | 2010 |
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
Topics: Abciximab; Acute Disease; Aged; Amino Acid Chloromethyl Ketones; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Citric Acid; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Kinetics; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 2002 |
Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Aged; Angina, Unstable; Cost-Benefit Analysis; Female; Follow-Up Studies; Health Care Costs; Hospital Costs; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Quality-Adjusted Life Years; Tirofiban; Tyrosine; United States | 2002 |
Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).
Topics: Acute Disease; Aged; Angina, Unstable; Cardiac Catheterization; Coronary Disease; Creatinine; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Renal Insufficiency; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Benefit of an early invasive management strategy in women with acute coronary syndromes.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Sex Factors; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2002 |
A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes.
Topics: Angina, Unstable; Coronary Angiography; Death, Sudden, Cardiac; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Female; Fibrinolytic Agents; Heart Conduction System; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Research Design; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
Topics: Aged; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Patient Admission; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Syndrome; Tirofiban; Treatment Outcome; Tyrosine; United Kingdom | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Topics: Aged; Angina, Unstable; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sex Factors; Syndrome; Tirofiban; Tyrosine | 2003 |
Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor.
Topics: Aged; Angina, Unstable; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
Topics: Acute Disease; Aged; Angina, Unstable; Biomarkers; C-Reactive Protein; Combined Modality Therapy; Creatine Kinase; Creatine Kinase, MB Form; Female; Fibrinolytic Agents; Humans; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Sex Factors; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Troponin; Tyrosine | 2004 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspirin; Blood Platelets; C-Reactive Protein; Cell Aggregation; Drug Resistance; Eptifibatide; Female; Heparin; Humans; Leukocytes; Male; Middle Aged; Monocytes; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Neutrophils; Patient Selection; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Receptors, Thrombin; Recurrence; ROC Curve; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy).
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Coronary Angiography; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Premedication; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Creatine Kinase; Creatine Kinase, MB Form; Double-Blind Method; Drug Interactions; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Isoenzymes; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Paclitaxel; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea
Topics: Abciximab; Acute Disease; Aged; Angina, Unstable; Antibodies, Monoclonal; Clopidogrel; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Necrosis; Prospective Studies; Syndrome; Ticlopidine; Time Factors; Tirofiban; Troponin I; Tyrosine | 2005 |
Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Double-Blind Method; Female; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Registries; Ticlopidine; Tirofiban; Tyrosine | 2007 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Thrombosis; Double-Blind Method; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIb-IX Complex; Postoperative Complications; Retreatment; Time Factors; Tirofiban; Tyrosine | 1997 |
The glycoprotein IIb/IIIa platelet receptor blocker tirofiban, but not heparin, counteracts platelet aggregation in unstable angina pectoris.
Topics: Aged; Angina, Unstable; Double-Blind Method; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1997 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine | 1998 |
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine | 1998 |
Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recurrence; Reoperation; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients.
Topics: Angina, Unstable; Heparin; Humans; Injections, Intravenous; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Tirofiban; Tyrosine | 1998 |
Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Th
Topics: Adolescent; Angina, Unstable; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Research Design; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
Topics: Aged; Amino Acid Sequence; Angina, Unstable; Blood Platelets; Cell Aggregation; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Fibrinogen; Flow Cytometry; Heparin; Humans; Male; Middle Aged; Molecular Sequence Data; Myocardial Infarction; Neutrophils; P-Selectin; Partial Thromboplastin Time; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Receptors, Thrombin; Tirofiban; Tyrosine | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Male; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome managemen
Topics: Aged; Angina, Unstable; Anticoagulants; Arteriosclerosis; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Thrombosis; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Confounding Factors, Epidemiologic; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Topics: Angina, Unstable; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Injections, Intravenous; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Uns
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Diabetes Complications; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin; Humans; Infusions, Intravenous; Likelihood Functions; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Collateral Circulation; Confidence Intervals; Coronary Circulation; Coronary Disease; Coronary Vessels; Double-Blind Method; Fibrinolytic Agents; Humans; Multivariate Analysis; Myocardial Infarction; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 2000 |
Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Canada; Cardiac Catheterization; Double-Blind Method; Female; Heparin; Hospitals; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Should patients with unstable coronary syndromes routinely undergo cardiac catheterization and appropriate revascularization?
Topics: Angina, Unstable; Cardiac Catheterization; Coronary Angiography; Humans; Myocardial Revascularization; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Biomarkers; Coronary Disease; Creatine Kinase; Creatine Kinase, MB Form; Electrocardiography; Endpoint Determination; Follow-Up Studies; Heparin; Humans; Isoenzymes; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Risk Assessment; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 2002 |
Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy; Blood Flow Velocity; Collateral Circulation; Coronary Circulation; Double-Blind Method; Fibrinolytic Agents; Humans; Myocardial Infarction; Prognosis; Tirofiban; Tyrosine | 2002 |
43 other study(ies) available for tirofiban and Angina at Rest
| Article | Year |
|---|---|
Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up.
Topics: Aged; Angina, Unstable; Biomarkers; C-Reactive Protein; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Kaplan-Meier Estimate; Male; Matrix Metalloproteinase 9; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Ticagrelor; Tirofiban; Tumor Necrosis Factor-alpha | 2021 |
[Two catheters for one coronary perforation].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Cardiac Catheterization; Catheters; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dyslipidemias; Femoral Artery; Heart Injuries; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Percutaneous Coronary Intervention; Premedication; Radial Artery; Stents; Tirofiban; Tyrosine | 2015 |
Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Eptifibatide; Female; Genotype; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Mutation; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Polymerase Chain Reaction; Prospective Studies; Tirofiban; Tyrosine | 2016 |
Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Acute Disease; Angina, Unstable; Coronary Angiography; Coronary Artery Bypass, Off-Pump; Follow-Up Studies; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Postoperative Complications; Preoperative Care; Risk Assessment; Severity of Illness Index; Thrombocytopenia; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Measuring the right compound at the right time is not always easy.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; C-Reactive Protein; Dose-Response Relationship, Drug; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Time Factors; Tirofiban; Tyrosine | 2010 |
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clopidogrel; Disease Management; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Health Behavior; Hemorrhage; Humans; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2002 |
Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cohort Studies; Female; Fibrinolytic Agents; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Multivariate Analysis; Nitrates; Observer Variation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbidity; Coronary Disease; Female; Hospitalization; Humans; Life Tables; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Severity of Illness Index; Stents; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.
Topics: Angina, Unstable; Diagnostic Errors; Fatal Outcome; Hemorrhage; Humans; Lung Diseases; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Edema; Radiography; Tirofiban; Tyrosine | 2004 |
Treatment of intracoronary thrombus using tirofiban in a patient with normal coronary arteries.
Topics: Angina, Unstable; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Fibrinolytic Agents; Humans; Male; Middle Aged; Tirofiban; Tyrosine | 2004 |
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Exercise Test; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Safety; Tirofiban; Tyrosine | 2004 |
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
Topics: Aged; Angina, Unstable; Anticoagulants; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Syndrome; Tirofiban; Tyrosine | 2005 |
Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Australia; Diabetic Angiopathies; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Syndrome; Tirofiban; Troponin; Tyrosine | 2006 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Inflammation; Male; Middle Aged; Postoperative Period; Premedication; Stents; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Biomarkers; Case-Control Studies; Confounding Factors, Epidemiologic; Coronary Angiography; Disease-Free Survival; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Life Expectancy; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Tirofiban; Tyrosine | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Angiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Registries; Stents; Syndrome; Tirofiban; Tyrosine | 2006 |
Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Topics: Acute Disease; Adult; Angina, Unstable; Blood Transfusion; Cerebral Hemorrhage; Creatinine; Disease Susceptibility; Dose-Response Relationship, Drug; Eptifibatide; Glomerular Filtration Rate; Hemorrhage; Hemorrhagic Disorders; Humans; Kidney Diseases; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Registries; Sex Characteristics; Tirofiban; Tyrosine | 2006 |
[Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Syndrome; Time Factors; Tirofiban; Tyrosine | 2006 |
Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Eptifibatide; Female; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2007 |
Pulmonary hemorrhage in a patient with acute coronary syndrome.
Topics: Aged; Angina, Unstable; Hemorrhage; Humans; Lung Diseases; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography; Tirofiban; Tyrosine | 2007 |
Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1998 |
Two new antiplatelet drugs for angioplasty and acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Premedication; Syndrome; Tirofiban; Tyrosine | 1998 |
Tirofiban in unstable coronary disease.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Tirofiban; Tyrosine | 1998 |
Super-aspirins in severe angina.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1998 |
GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Cost-Benefit Analysis; Disease Management; Drug Costs; Eptifibatide; Evidence-Based Medicine; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; United States | 1999 |
Cost-effective treatment of acute coronary syndromes-IIB or not IIB?
Topics: Angina, Unstable; Cost-Benefit Analysis; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Switzerland; Tirofiban; Tyrosine | 1999 |
Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial.
Topics: Angina, Unstable; Cost of Illness; Cost-Benefit Analysis; Fibrinolytic Agents; Heparin; Hospitalization; Humans; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Switzerland; Tirofiban; Tyrosine | 1999 |
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 1999 |
Tirofiban and intracoronary stenting: evaluation of a new pharmacologic regimen.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Tirofiban; Tyrosine | 1999 |
The role of tirofiban in acute coronary syndromes.
Topics: Angina, Unstable; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombosis; Tirofiban; Tyrosine | 2000 |
Drip and ship: a new strategy for the treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Protocols; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hospitalization; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Nitrates; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heart Failure; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Regression Analysis; Risk Factors; Statistics, Nonparametric; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2000 |
Tirofiban counteracts pending myocardial infarction.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Drug Monitoring; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2000 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherectomy; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 2000 |
Fast, aggressive treatment for myocardial infarction urged.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Stents; Tirofiban; Tyrosine | 2000 |
[New thrombocyte aggregation inhibitor in therapy of unstable angina].
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2000 |
[Risk stratification in acute coronary syndrome].
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clinical Trials as Topic; Coronary Disease; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Retrospective Studies; Risk Factors; Syndrome; Terminology as Topic; Tirofiban; Troponin I; Troponin T; Tyrosine | 2001 |
Exit of platelet glycoprotein-IIb/IIIa-receptor inhibitors?
Topics: Aged; Angina, Unstable; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematoma; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Streptokinase; Thrombolytic Therapy; Tirofiban; Tyrosine | 2001 |
A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris.
Topics: Adult; Age Distribution; Aged; Angina, Unstable; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heparin; Humans; Male; Middle Aged; Myocardial Ischemia; Odds Ratio; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Probability; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Sex Distribution; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
[Antithrombotic therapy of unstable angina pectoris].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Ticlopidine; Tirofiban; Tyrosine | 1998 |
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |